Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
25.6M
-
Shares change
-
+1.03M
-
Total reported value, excl. options
-
$372M
-
Value change
-
+$16.6M
-
Number of buys
-
39
-
Number of sells
-
-43
-
Price
-
$14.51
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2022
107 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q3 2022.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.6M shares
of 50M outstanding shares and own 51.28% of the company stock.
Largest 10 shareholders include Deep Track Capital, LP (1.82M shares), TANG CAPITAL MANAGEMENT LLC (1.8M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.71M shares), BlackRock Inc. (1.71M shares), Frazier Life Sciences Management, L.P. (1.57M shares), GREAT POINT PARTNERS LLC (1.55M shares), Vivo Capital, LLC (1.53M shares), FMR LLC (1.16M shares), VANGUARD GROUP INC (1.15M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.08M shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.